Scopolamine Patches: Transdermal Prevention for Motion Sickness, Sea Sickness, Nausea and Drooling
FOR HEALTHCARE PROFESSIONALS ONLY — This content is intended exclusively for registered medical practitioners, pharmacists, and accredited healthcare facilities. If you are a patient or consumer, please consult your healthcare provider. A scopolamine patch for motion sickness offers a recognised and effective transdermal option for preventing travel-related nausea while also supporting the management of seasickness, drooling, and associated symptoms. In Australia, transdermal scopolamine may be accessed by healthcare professionals under the Therapeutic Goods Administration (TGA) Special Access Scheme (SAS), where clinically appropriate and when no suitable registered alternative exists. HL Pharma supports authorised healthcare providers with compliant access to unregistered medicines through the TGA SAS framework, ensuring every process aligns with ISO 9001:2015 and Good Distribution Practice (GDP) principles.
How the Scopolamine Transdermal Patch Works
Each transdermal scopolamine patch delivers a controlled dose of scopolamine, a muscarinic receptor antagonist that acts on the central nervous system. The medicine works by blocking acetylcholine signals within the vestibular and vomiting centres of the brain, which regulate balance, nausea and salivation. By reducing nerve transmission between the inner ear and the brain’s emetic centre, scopolamine helps prevent the onset of motion sickness, nausea and excessive drooling. The transdermal patch system ensures a steady release of medicine through the skin behind the ear over 72 hours, maintaining consistent plasma levels and continuous symptom control.
Therapeutic Use
While best known for motion sickness prevention, the Scopolamine Patch is also used in clinical settings where control of refractory nausea or excessive salivation is required. Healthcare professionals in oncology or palliative settings who are managing refractory nausea may assess TGA SAS eligibility under their clinical governance framework. These combined actions make transdermal scopolamine a valuable option for motion sickness, nausea relief and drooling management across both travel-related and therapeutic settings.
Access in Australia through the TGA Special Access Scheme
In Australia, Scopolamine Patches are not registered for general use. Access is available under the TGA Special Access Scheme (SAS) for specific clinical circumstances, allowing healthcare professionals to apply for SAS Category B approval where an unregistered medicine is clinically appropriate. This framework ensures patient access remains under strict medical supervision and regulatory oversight. HL Pharma facilitates compliant sourcing and supply of unregistered medicines under the SAS, maintaining full traceability and regulatory confidence.
Summary
The Scopolamine Transdermal Patch provides a proven pharmacological approach for preventing motion sickness and managing nausea and excessive salivation. Through a 72-hour controlled-release system, it delivers consistent and reliable symptom management. For Australian healthcare professionals, access to transdermal scopolamine is available through the TGA Special Access Scheme, ensuring every supply process is supported by HL Pharma’s commitment to quality, compliance and patient safety.
References
American Journal of Physical Medicine & Rehabilitation. The Use of Transdermal Scopolamine to Control Drooling, 1991. Therapeutic Goods Administration (TGA). Special Access Scheme Guidance, 2024. FDA Drug Label: Transderm Scōp (Scopolamine Transdermal System). PubMed: Scopolamine in Motion Sickness, Nausea and Drooling Management, 2023.
HL Pharma supports authorised healthcare professionals and licensed facilities in facilitating access to unregistered medicines through established TGA regulatory frameworks. Supply is subject to valid clinical justification and appropriate regulatory approval. HL Pharma does not supply medicines directly to patients or consumers.